Abstract 133P
Background
The use of CAR-T therapy for treating solid tumors has encountered challenges due to the structure and immunological properties of the tumors. However, microvesicles, which represent cell-free biosimilar drugs, offer a promising solution to overcome these obstacles. One of the main issues faced in this approach is the small yield of microvesicles from the cell sources. This challenge can be addressed by incorporating various induction methods such as ultrasonication.
Methods
T lymphocytes and anti-CD19 CAR-T cells were activated by CD3/CD28 abs for 24 h, then ultrasonication was used to obtain artificial vesicles (AVs) – T-AVs and CAR-T-AVs, respectively. AVs were isolated by differential centrifugation and analyzed with scanning electron microscopy (SEM) using Merlin (Carl Zeiss). Then the cytotoxic efficacy of AVs against PC3M and PC3M(CD19+) tumor cells was tested using xCelligence real-time cell analysis (RTCA) system.
Results
SEM data: CAR-T-AVs (n=263) were predominantly smaller in size than T-AVs (n=376). The major population was represented by 51-75 nm particles with a narrow monodisperse peak. Whereas for T-AVs, most particles the size distribution was much wider, in the range of 75-200 nm. RTCA data: for PC3M control, neither added T/CAR-T cells nor their respective AVs had any significant effect on tumor cell proliferation. Opposite to that, for the PC3M(CD19+) tumor line, the cell index began to decrease 30 hrs after CAR-T-AVs addition – interestingly, with more pronounced effect in the wells with a lower concentration of vesicles (10 μg/ml). Both T-AVs and CAR-T-AVs showed a less pronounced cytotoxic effect at higher concentration (35 μg/ml), potentially due to nonspecific toxicity.
Conclusions
Ranging particles size distribution may indicate diverse dynamics in the cell membrane and intracellular content in response to activation of T/CAR-T cells and treatment with ultrasonic. Doze-dependence of CAR-T-AVs cytotoxicity and their detailed mechanism of action shall be addressed in the future studies. The work was funded by the Russian Science Foundation grant 23-24-00224 and performed in accordance with the Strategic Academic Leadership Program of the Kazan (Volga Region) Federal University (PRIORITET-2030).
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
The work was funded by the Russian Science Foundation grant 23-24-00224 and performed in accordance with the Strategic Academic Leadership Program of the Kazan (Volga Region) Federal University (PRIORITET-2030).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
83P - Evaluation of serum macrophage inhibitory cytokine 1 as a diagnostic biomarker for pancreatic cancer: A systematic review and diagnostic accuracy meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Profiling of lipid-loaded macrophages in melanoma
Presenter: Marta Pandini
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Whole-genome CRISPR screening identifies chemosensor receptors as key regulators of the cancer-macrophage crosstalk
Presenter: Giulia Marelli
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Regulation of cancer progression through the gut microbiome and immuno-nutrition
Presenter: Anikka Swaby
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Macrophage ontogeny underlies functional programs and drives brain tumor progression
Presenter: Miranda Yu
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluating the infiltration of anti-NKG2DL CAR-T cells into a 3D cell culture developed in a Vitvo cartridge bioreactor
Presenter: Aigul Valiullina
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Neutrophils as producers of endothelial growth factor in the progression of kidney cancer
Presenter: Ilseya Myagdieva
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: A systematic review
Presenter: Omar Mubarak
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Reduction in the relative lymphocyte count as a predictive biomarker for serious immune-related adverse events in patients with metastatic non-small cell lung cancer on immunotherapy: Single institution experience
Presenter: Antoan Garev
Session: Cocktail & Poster Display session
Resources:
Abstract